Icosapent ethyl for hypertriglyceridaemia and atherosclerosis: greater RESPECT for increased therapeutic use

Eur Heart J. 2024 Feb 7;45(6):439-442. doi: 10.1093/eurheartj/ehad668.

Authors

Prakriti Gaba¹, Deepak L Bhatt², William E Boden³

Affiliations

¹ Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
² Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, 1 Gustave Levy Place, Box 1030, New York, NY 10029, USA.
³ Division of Cardiovascular Medicine, Boston University School of Medicine, Boston, MA, USA.

No abstract available

MeSH terms

Atherosclerosis* / drug therapy
Cardiovascular Diseases* / drug therapy
Eicosapentaenoic Acid / analogs & derivatives*
Eicosapentaenoic Acid / therapeutic use
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
Hyperlipidemias* / drug therapy
Hypertriglyceridemia* / complications
Hypertriglyceridemia* / drug therapy
Triglycerides

Substances

eicosapentaenoic acid ethyl ester
Eicosapentaenoic Acid
Triglycerides
Hydroxymethylglutaryl-CoA Reductase Inhibitors